Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Post-EHA & ICML 2025 Lymphoma Highlights
05 September 2025 | Virtual Meeting
Post-EHA & ICML 2025 Lymphoma Highlights
Featuring presentations & discussions on selected lymphoma abstracts from the 30th Congress of the European Hematology Association (EHA) & the 18th International Conference on Malignant Lymphoma (ICML).
Chair: Caron Jacobson | Moderators: Kate Cwynarski & John Kuruvilla
The Post-EHA & ICML 2025 Lymphoma Highlights webinar has been supported by Takeda (Gold Sponsorship) and Genentech (Gold Sponsorship). Supporters have had no influence over the production of this activity.
Session 1: Advances in the management of MCL, FL & MZL
Lisocabtagene maraleucel in patients with R/R MZL: Phase II TRANSCEND FL study
M. Lia Palomba Memorial Sloan-Kettering Cancer Center, New York City, NY, United States
Fixed-duration subcutaneous mosunetuzumab + polatuzumab vedotin in patients with R/R post-BTKi MCL
Michael Wang The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Rituximab-bendamustine with or without acalabrutinib in patients with untreated, high-risk MCL: an analysis of the Phase III ECHO trial
Martin Dreyling Ludwig Maximilian University of Munich, Munich, Germany
Extended follow-up of the MITHIC-FL1 trial: mosunetuzumab in patients with newly diagnosed FL
Gilles Salles Memorial Sloan Kettering Cancer Center, New York, NY, United States
Panel discussion
Session 2: Novel treatment approaches in Hodgkin lymphoma
Pembrolizumab and radiation therapy alone as an alternative to transplant for localized failure after chemotherapy in HL
Alexandra Dreyfuss Memorial Sloan Kettering Cancer Center, New York City, United States
5-year update on frontline brentuximab vedotin + AVD for stage II-IV HIV-associated classical HL
Paul Rubinstein University of Illinois Chicago, Chicago, IL, United States
Panel discussion
Session 3: Latest in targeted immunotherapy-chemotherapy combinations for DLBCL
Results from the Phase III POLARGO trial: pola-R-GemOx for R/R DLBCL
Matthew Matasar Rutgers Cancer Institute, New Brunswick, NJ, United States
EPCORE NHL-5: fixed-duration epcoritamab + pola-R-CHP for frontline diffuse large B-cell lymphoma
Alan Kerr Tampa General Hospital, Tampa, FL, United States
A multicenter Phase II study of glofitamab plus pola-R-CHP for patients with high-risk DLBCL
Jennifer Crombie Dana-Farber Cancer Institute, Boston, MA, United States
Glofitamab + GemOx in patients with R/R DLBCL: 2-year follow-up of STARGLO
Jeremy Abramson Massachusetts General Hospital Cancer Center, Boston, MA, United States
Panel discussion
Session 4: Advances with CAR-T, ADCs & T-cell engagers in LBCL
A Phase I study of KITE-363 in patients with R/R B-cell lymphoma
Saurabh Dahiya Stanford Medicine, Stanford, CA, United States
Phase I/II study of LYL314, a novel CD19/CD20-targeting CAR T-cell, in patients with R/R LBCL
Akil Merchant Cedars-Sinai Medical Center, Los Angeles, CA, United States
A global Phase Ib study of JNJ-90014496 in patients with R/R LBCL
Krish Patel Sarah Cannon Research Institute, Nashville, TN, United States
Primary results from the Phase III SUNMO trial: mosunetuzumab plus polatuzumab vedotin in transplant-ineligible R/R LBCL
Jason Westin The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Initial results from the Phase Ib LOTIS-7 trial: loncastuximab tesirine plus glofitamab in patients with R/R DLBCL
Juan Alderuccio Sylvester Comprehensive Cancer Center, Miami, FL, United States
Panel discussion
